One of pharma’s biggest success stories in recent years and one of venture capital’s major players in the life sciences, Shire PLC and Atlas Venture, have agreed to a multi-year collaboration to incubate early-stage research programs for rare disease therapeutics.
Under the deal announced Dec. 15, representatives from Shire and Atlas will work together to vet research proposals worthy of being housed in start-up biotechs, which would be co-financed by the two entities
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?